Human rabies virus immune globulin
Identification
- Name
- Human rabies virus immune globulin
- Accession Number
- DB11603
- Description
IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.
Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine.
IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.
Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Polyclonal antibody (pAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Rabies immune globulin
- Rabies immune globulin (human)
- Rabies immune globulin human
- Rabies immune globulin, human
- Rabies immune globulin,human
- Rabies immunoglobulin (human)
- Rabies immunoglobulins
Pharmacology
- Indication
For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine [FDA Label].
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Rabies immune globulin prevents viral invasion of the central nervous system.
- Mechanism of action
Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system [FDA Label]. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.
Target Actions Organism ARabies Virus Proteins antibodyRabies virus (strain Pasteur vaccins / PV) - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted [FDA Label].
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbatacept The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
Purchasing individual compounds or compound libraries for your research?
Learn More- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataHyperab Rabies Immune Globulin Human Liquid Intramuscular Cutter Med & Biol, Division Of Miles Canada Ltd. 1985-12-31 1998-09-25 Canada 
HyperRAB Solution 300 unit Intramuscular Grifols Therapeutics Llc 2019-07-02 Not applicable Canada HyperRAB Injection, solution 300 [iU]/1mL Infiltration; Intramuscular GRIFOLS USA, LLC 1974-06-12 Not applicable US 
Hyperrab S/d Injection 150 [iU]/1mL Intramuscular GRIFOLS USA, LLC 1996-08-14 Not applicable US Hyperrab S/d Solution 150 unit Intramuscular Grifols Therapeutics Llc 1997-10-09 Not applicable Canada Imogam Rabies Inj 150unit/ml Liquid Intramuscular Pasteur mÉrieux Serums Et Vaccins, s.a. 1991-12-31 1999-08-12 Canada Imogam Rabies Pasteurized Solution Intramuscular Sanofi Pasteur Limited 1999-04-30 Not applicable Canada Imogam Rabies-HT Injection, solution 150 [iU]/1mL Intramuscular Sanofi Pasteur Inc. 1984-04-27 Not applicable US Kamrab Solution Intramuscular Kamada Ltd 2020-04-06 Not applicable Canada Kamrab Solution Intramuscular Kamada Ltd Not applicable Not applicable Canada Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 95F619ATQ2
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- AHFS Codes
- 80:04.00 — Serums
- 80:12.00 — Vaccines
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Rabies 2 4 Recruiting Treatment Primary Immune Deficiency (PID) 1 4 Withdrawn Prevention Virus Diseases 1 3 Active Not Recruiting Prevention Virus Diseases 1 3 Completed Prevention Children, Only / Malaria caused by Plasmodium falciparum 1 3 Completed Prevention Plasmodium Infections 1 3 Completed Prevention Rabies Infection 1 3 Completed Prevention Rabies Prevention 1 3 Recruiting Prevention Rabies (Healthy Volunteers) 3 3 Recruiting Treatment Rabies 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution 1500 iu/10mL Injection, solution 300 iu/2mL Injection, solution Intramuscular 135 mg/ml Solution Intramuscular; Subcutaneous 1000 iu/5ml Injection, solution 750 iu/5mL Injection, solution Infiltration; Intramuscular 300 [iU]/1mL Solution Intramuscular 300 unit Injection Intramuscular 150 [iU]/1mL Solution Intramuscular 150 unit Liquid Intramuscular Solution Intramuscular Injection, solution Intramuscular 150 [iU]/1mL Powder, for solution Intramuscular 2.5 IU/mL Injection, powder, for solution Intramuscular 1 ml Injection, powder, for solution Intramuscular 2.5 IU - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
- Kind
- Protein group
- Organism
- Rabies virus (strain Pasteur vaccins / PV)
- Pharmacological action
- Yes
- Actions
- Antibody
- General Function
- Attaches the virus to host cellular receptor, inducing endocytosis of the virion. In the endosome, the acidic pH induces conformational changes in the glycoprotein trimer, which trigger fusion between virus and cell membrane. There is convincing in vitro evidence that the muscular form of the nicotinic acetylcholine receptor (nAChR), the neuronal cell adhesion molecule (NCAM), and the p75 neurotrophin receptor (p75NTR) bind glycoprotein and thereby facilitate rabies virus entry into cells (By similarity).
- Specific Function
- Not Available
Components:
| Name | UniProt ID |
|---|---|
| Glycoprotein | P08667 |
| Large structural protein | P11213 |
| Matrix protein | P08671 |
| Nucleoprotein | P06025 |
| Phosphoprotein | P06747 |
References
- Sikes RK: Human rabies immune globulin. Public Health Rep. 1969 Sep;84(9):797-801. [PubMed:4185138]
- Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, Kuzmin IV, Marissen WE, Rupprecht CE: In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3). pii: tropicalmed2030048. doi: 10.3390/tropicalmed2030048. [PubMed:30270905]
Drug created on June 01, 2016 14:49 / Updated on November 25, 2020 08:53
![]({"CS-Molecular-Health-1.jpg":"/assets/linkouts/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/linkouts/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/linkouts/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/linkouts/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/linkouts/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/linkouts/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/linkouts/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/linkouts/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/linkouts/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/linkouts/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/linkouts/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/linkouts/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/linkouts/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/linkouts/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/linkouts/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/linkouts/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/linkouts/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/linkouts/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/linkouts/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/linkouts/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})